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Ficolinsarethoughttobepathogen-associated-molecular-pattern-(PAMP-)recognitionmolecules thatfunctiontosupportinnate
immunity.Likemannose-bindinglectins(MBLs),mostmammalianﬁcolinsformcomplexeswithMBL-associatedserineproteases
(MASPs),leadingtocomplementactivationviathelectinpathway.However,theabilityofmurineﬁcolinB,ahomologueofhuman
M-ﬁcolin, to perform this function is still controversial. The results of the present study show that ﬁcolin B in mouse bone marrow
is an oligomeric protein. Ficolin B, pulled down using GlcNAc-agarose, contained very low, but detectable, amounts of MASP-2
and small MBL-associated protein (sMAP) and showed detectable C4-deposition activity on immobilized N-acetylglucosamine.
These biochemical features of ﬁcolin B were conﬁrmed using recombinant mouse ﬁcolin B produced in CHO cells. Taken together,
these results suggest that like other mammalian homologues, murine ﬁcolin B has an ability to exert its function via the lectin
pathway.
1.Introduction
Ficolins (FCN/Fcn) are a family of proteins comprising a
collagen-like and a ﬁbrinogen-like domain [1] the latter
binding speciﬁcally to N-acetyl compounds such as N-
acetylglucosamine (GlcNAc) [2–4]. Three types of ﬁcolin
have been identiﬁed in humans: L-FCN [1, 5], M-FCN
[6, 7], and H-FCN [8]. Transcripts for L-FCN and H-
FCN are mainly produced in the liver, and the proteins
circulate as serum ﬁcolins, whereas the mRNA for M-FCN
is expressed mainly in peripheral monocytes and the protein
ispresentintheserumatlowconcentrations[9].Twoﬁcolins
have been identiﬁed in mice: ﬁcolin A (FcnA) and ﬁcolin
B( F c n B )[ 10, 11]. FcnA mRNA is mainly expressed in
Kupﬀer cells in the liver [12], and the protein is present in
serum. FcnB mRNA is mainly expressed in cells of myeloid
cell lineage within the bone marrow [12]. The location
of FcnB protein is still unclear, although it is reported to
localize within the lysosomes of activated macrophages [13].
Our phylogenetic analyses show that FcnB is the murine
orthologue of human M-FCN, that FcnA and L-FCN were
independently diverged in the murine and primate lineages,
respectively, from the ancestral FcnB/M-FCN, and that the
H-FCN gene is a pseudogene in the murine lineage [14]. In
addition, our previous ontogenetic study showed that the
spatial-temporal expression pattern was diﬀerent for FcnB
and FcnA, suggesting that each of the ﬁcolins might have a
speciﬁc role in the prenatal and postnatal stages [12].
Thus, ﬁcolins are roughly classiﬁed into two groups:
a serum type (plasma type), which includes L-FCN, H-
FCN and FcnA produced mainly in the liver and present
in the circulation as serum lectins [15] and a nonserum
type (nonplasma type), which includes M-FCN and FcnB
hardly detectable in the serum. The latter group, particularly
murine FcnB, has not been studied in detail at the protein
level, because of diﬃculties in identifying and isolating
as u ﬃcient amount of the protein. There are no reports
regarding the biochemical features of native FcnB.2 Journal of Biomedicine and Biotechnology
To date, we have shown that mammalian ﬁcolins, includ-
ing three human ﬁcolins and mouse FcnA, associate with
mannose-binding lectin (MBL)-associated serine proteases
(MASPs) and activate the lectin pathway [5, 16–18]. We
also reported that recombinant mouse FcnB produced in
DrosophilaS2cellsdoesnotassociatewithMASP-2andsmall
MBL-associated protein (sMAP) [18]. Recently, however,
it was reported that rat recombinant FcnB associates with
MASPs and activates the lectin pathway by binding to
PAMPs [19]. In the present study, we carefully examined
the biochemical properties of FcnB using both native FcnB
isolated from mouse bone marrow ﬂuid, and recombinant
mouse FcnB produced in CHO cells. The results show that
like rat FcnB, mouse FcnB has the ability to form complexes
with MASPs and sMAP.
2.MaterialsandMethods
2.1. Preparation of FcnB from Mouse Bone Marrow. To avoid
complications resulting from the co-presence of FcnA and
FcnB, the bone marrow tissue used as the source of
FcnB was collected from FcnA-deﬁcient mice generated on
a C57BL6 background by gene targeting (manuscript in
preparation).Thebonemarrow ﬂuidandcellswerecollected
assupernatantandprecipitate,respectively,bycentrifugation
ofthepooledtissueat10,000×gfor10min.Thesupernatant
was then subjected to aﬃnity chromatography on a GlcNAc-
agarose column. The bound fraction was eluted sequentially
with 0.3M mannose and then with 0.3M GlcNAc. The
recovered eluate was dialyzed against 50mM Tris-HCl, at
pH 7.5, containing 0.15M NaCl and 2.5mM CaCl2 (TBS-
Ca), concentrated in a centrifugal ﬁlter (Amicon Ultra-4,
Millipore, Billerica, MA, USA) and stored at −80◦C until
required. The GlcNAc-eluate was used as a source of native
FcnB in further study.
2.2. Preparation of Recombinant FcnB (rFcnB). Full-length
mouseFcnBcDNAwasconstructedin apIRCMVvectorand
cotransfected with a pFerH vector encoding a transposase
into CHO cells as previously described [20]. The rFcnB-
producing CHO cells were screened by culturing in the pres-
ence of 0.5mg/mL neomycin G-418. After several passages
in DMEM medium containing 10% FCS, the neomycin-
resistant CHO cells were cultured in a serum-free medium
(CHO-S-SFM, GIBCO, Grand Island, NY, USA). The rFcnB
secreted into the culture medium was puriﬁed on a GlcNAc-
agarose column. Brieﬂy, after washing the column with
TBS containing 0.05% Tween-20, 0.1M mannose, 0.1M
galactose, and 0.1M glucose, the bound fraction was eluted
with 0.3M GlcNAc. The eluate was dialyzed against TBS-
Ca, concentrated, and stored at −80◦C until use. The N-
terminal amino acid sequence of rFcnB was determined
using a Procise cLC Protein Sequencing System (Applied
Biosystems, Poster City, CA, USA). The rFcnB produced by
CHO cells was simply termed rFcnB in this study, while
rFcnB produced previously in Drosophila S2 cells was termed
rFcnBs2-1 [18]. The recombinant protein concentration was
determined using a BCA protein assay kit (Pierce, Rockford,
IL, USA) with BSA as a standard protein.
2.3. Preparation of Recombinant Mouse MASP-1, MASP-2,
MASP-3, and sMAP. Two recombinant forms of mature
mouse MASP-2 were produced in Drosophila S2 cells with
a histidine (His)-tag as previously described [21]: one com-
prised the normal sequence with protease activity (rMASP-
2a) and the other a mutated sequence (Ser632Ala) with no
activity (rMASP-2i). Recombinant mouse MASP-1 (rMASP-
1i) was prepared in a His-tagged form using a Baculovirus
expressionsystem(Invitrogen,Carlsbad,CA,USA),andisan
inactive form harboring a mutated catalytic site (Ser646Ala)
[22]. Recombinant mouse MASP-3 (rMASP-3) [23]a n d
sMAP (rsMAP) [21] were prepared as His-tagged forms in
DrosophilaS2cells.Allrecombinants(rMASP-1i,-2i,-2aand
-3, and rsMAP) were puriﬁed by aﬃnity chromatography on
Ni-NTA agarose columns (Qiagen Inc., Valencia, CA, USA)
followed by elution with imidazole. The recombinant pro-
teins were dialyzed against TBS, concentrated, and stored at
−80◦C until use. The protein concentration was determined
as described above.
2.4. Western Blotting for FcnB, MBLs, MASPs, and sMAP.
SDS-PAGE was performed on 10% polyacrylamide gels
under reducing conditions according to the method of
Laemmli. After electrophoresis, the proteins were transferred
to a polyvinylidene diﬂuoride membrane ﬁlter (Millipore,
Billerica, MA, USA). The membrane ﬁlter was blocked with
BlockingOnereagent(NacalaiTesqueInc.,Kyoto,Japan)and
probed with 500∼2000-fold-diluted polyclonal antibodies
(Abs) against mouse FcnB and MASP-2/sMAP [18, 21]a n d
500-fold-diluted monoclonal Abs against MBL-A and MBL-
C (clones 8G6 and 16A8, resp., Hycult Biotechnology, Uden,
The Netherlands) in 10mM phosphate buﬀer, at pH 7.4,
containing 137mM NaCl and 2.7mM KCl (PBS) containing
0.1% Tween-20 (PBS-T). For the detection of MASP-1 and
-3, a monoclonal anti-penta-His-tag Ab (Qiagen) was used
as the primary Ab. After washing, the ﬁlters were further
incubated with either HRP-conjugated secondary Abs or
biotinylated secondary Abs (Dako Cytomation, Glostrup,
Denmark) followed by an avidin-biotinylated HRP complex
(VectorLab.,Burlingame,CA, USA).Finally,themembranes
were developed using a chemiluminescent substrate (ECL,
Amersham Biosciences, Buckinghamshire, UK). The chemi-
luminescent image was analyzed using an LAS-3000 (Fuji
ﬁlm, Tokyo, Japan).
2.5. Treatment of FcnB with Endoglycosidases. The N-linked
carbohydratesexpressedonFcnBwereremovedbytreatment
with endoglycosidase F (EMD Biosciences Inc., La Jolla,
CA, USA) as previously described [24]. Selective removal
of O-linked glycans was achieved by treatment with 0.1U
neuraminidase (Wako Pure Chemicals, Osaka, Japan) and
20mU endo-α-N-acetylgalactosaminidase (Seikagaku Co.,
Tokyo, Japan) at 37◦Cf o r1 6h .Journal of Biomedicine and Biotechnology 3
2.6. Gel Filtration Chromatography of FcnB. To estimate the
size distribution of oligomeric FcnB, the FcnB preparations
were subjected to gel ﬁltration chromatography using a
Superose610/300GLcolumnequilibratedwithPBSandcon-
nected to an ¨ AKTA puriﬁer system (Amersham Biosciences,
Uppsala, Sweden). An aliquot of each recovered fraction
(0.5mL/fraction) was assessed for FcnB by western blotting
under reducing conditions.
2.7. Complex Formation of rFcnB with rMASPs and rsMAP.
rFcnB was incubated with rMASPs and rsMAP at a molar
ratioof3:1:8(rFcnB:rMASPs:rsMAP)overnightat4 ◦Ci n
TBS containing 2.5mM CaCl2, 3% BSA, and 0.05% Tween-
20 as previously described [18]. The above molar ratio was
chosen by reference to the concentrations of FcnA, MASP-2,
andsMAPinthemouseserum[18].Themixturewasfurther
incubated with a GlcNAc-agarose slurry (50%, 40μL) at 4◦C
for 3hr to pull down rFcnB, and the bound fraction was
eluted with 0.3M GlcNAc. The eluate was dialyzed against
TBS-Ca and the ﬁnal sample subjected to western blotting
and a C4-deposition assay. For western blotting, rMASP-2i
was used as a source of MASP-2 to ensure clear results, since
itisknownthatrMASP-2aisconverted,inpart,intoitsactive
form, comprising the heavy and light chains connected via
a disulﬁde bond, during puriﬁcation. For the C4-deposition
assay, MASP-2a was used as the source of MASP-2 instead of
rMASP-2i. Similar autoactivation is also seen with rMASP-1;
therefore, rMASP-1i was used as the source of MASP-1 for
western blotting to detect complex formation with rFcnB.
2.8. C4-Deposition Assay. C4-deposition activity was deter-
mined by ELISA as previously described [18]. Brieﬂy,
the GlcNAc eluates prepared from bone marrow ﬂuid or
the rFcnB/rMASP-2a/sMAP complexes, were incubated in
100μL of TBS-Ca at 37◦Cf o r1 0 m i ni naG l c N A c - B S A -
coated microtiter plate. The plate was then incubated with
human C4 on ice for 30min, followed by washing with
PBS-T. The C4b generated on the plate was detected with
an HRP-conjugated sheep anti-human C4b Ab (Biogenesis,
Poole, UK) and color developed using TMB (KPL Co.,
Gaithersburg, MD, USA) and H2O2 as substrates. After
termination of the reaction with 0.5M H3PO4, the plates
were read at 450nm in a Multimode detector DTX880
(Beckman Coulter Inc., Brea, CA, USA).
3. Results
To detect the FcnB protein in the bone marrow, the tissue
supernatants and precipitates were subjected to western
blotting. As shown in Figure 1(a),a3 8 k D ab a n dw a s
observed in the supernatant under reducing conditions,
suggestingthatFcnBissecretedintothemousebonemarrow
ﬂuid as a soluble protein. FcnB was also detected as a 37kDa
band at high levels in the precipitate. This suggests that FcnB
in bone marrow cells is slightly small due to incomplete
processing prior to secretion. When FcnB in the supernatant
was treated with endoglycosidase F, its molecular weight
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Figure 1: Characterization of FcnB in the mouse bone marrow.
(a) Western blotting of FcnB in the supernatant (lane 1) and
precipitate (lane 2) of bone marrow tissue, and plasma (lane 3)
(left panel). Two μL of the supernatant/precipitate equivalent to
the original tissue and 2μLo fp l a s m af r o mF c n A −/− mice were
subjected to western blotting under reducing conditions. FcnB in
the supernatant (4μL equivalent to the original tissue) was treated
with endoglycosidase F (endoF) or neuraminidase plus endo-α-N-
acetylgalactosaminidase (o-gly) and subjected to western blotting
(right panel).—, not treated. (b) Superose 6 gel chromatography
of FcnB in the bone marrow supernatant from FcnA−/− mice. An
aliquot of each fraction was subjected to western blotting under
reducing conditions. Arrowheads depict the eluted positions of
the molecular weight markers (661kDa, thyroglobulin; 440kDa,
ferritin; 230kDa, catalase; 67kDa, BSA).
reduced from 38 to 34kDa, whereas treatment with endo-α-
N-acetylgalactosaminidase resulted in either no or a smaller
reduction in molecular weight (Figure 1(a)). To determine
the size distribution of oligomeric FcnB, the supernatant was
subjected to gel chromatography. FcnB was recovered from
fractions corresponding to the elution positions of marker
proteins ranging from 100 to >1000kDa with a peak around
600kDa (Figure 1(b)), indicating a heterogeneous structure
composed mainly of 12–18-mers.
Next, the bone marrow supernatant was subjected to
GlcNAc-agarose aﬃnity chromatography to purify FcnB. As
shown in Figure 2(a), FcnB was recovered in the GlcNAc
eluate, whereas MBL-A and MBL-C (MBLs) were recov-
ered in the mannose eluate. The mannose eluate included
signiﬁcant amounts of the MASP-2 pro-enzyme, MASP-2
heavy chain, and sMAP. This suggests that MBLs are present
in the bone marrow ﬂuid as complexes with MASP-2 and
sMAP. Interestingly, trace amounts of MASP-2 and sMAP
were also detected in the GlcNAc eluate, suggesting that at
least a part of FcnB also exists in complex with MASP-2
and sMAP. This GlcNAc eluate showed C4-deposition on
GlcNAc-coated microplates (Figure 2(b)), although the level
was very low compared with that of the mannose eluate.
This activity was signiﬁcantly decreased by passage of the
eluate through anti-FcnB Ab-coupled Sepharose 4B. These
results suggest that the FcnB/MASPs complexes can activate
complement component C4 through the lectin pathway.
To conﬁrm the above results, rFcnB was produced in
CHO cells and puriﬁed by GlcNAc-agarose chromatogra-
phy. Western blotting showed that rFcnB consisted of a
monomerwithamolecularweightof37kDa;slightlysmaller4 Journal of Biomedicine and Biotechnology
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Figure 2: : GlcNAc-agarose chromatography of bone marrow ﬂuids from FcnA−/− mice. (a) Western blot of FcnB, MBL-A, MBL-C, and
MASP-2/sMAPinthemannose(M)andGlcNAc(G)eluatesfromGlcNAc-agarosechromatographyunderreducingconditions.Rightpanel:
90kDa, 58kDa, and 23kDa bands represent the proenzyme form of MASP-2, the heavy chain of MASP-2, and sMAP, respectively. For each
sample, 60μL equivalent to the original volume of bone marrow tissue was loaded per lane. (b) C4-deposition activity of the GlcNAc eluate
on GlcNAc-BSA-coated microplates. Before assessment, the GlcNAc eluate was passed through anti-FcnB Ab-coupled Sepharose 4B (Ab+)
or not (Ab−). The activity of a 30μL sample equivalent to the original bone marrow tissue was determined in quadruplicate (mean ± SD).
Inset: western blot of FcnB in the eluates used for C4 deposition.
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Figure 3: Structural characterization of rFcnB. (a) Left panel: Western blot of rFcnB and rFcnBs2-1 treated with endoglycosidase
F (endoF). Right panel: western blot of rFcnB and rFcnBs2-1 treated with neuraminidase (neu) or neuraminidase plus endo-α-N-
acetylgalactosaminidase (o-gly). Western blotting was performed under reducing conditions. —, not treated. (b) Gel chromatography of
rFcnB (upper panel) and rFcnBs2-1 (lower panel). rFcnB or rFcnBs2-1 (400μL; 5–10μg) was applied to a Superose 6 column (1cm φ×
30cm) and fractionated into 0.5mL/fractions. An aliquot of each fraction was subjected to western blotting for FcnB under reducing
conditions.
than native FcnB, but larger than rFcnBs2-1 (33–35kDa)
(Figure 3(a)). Upon treatment with endoglycosidase F, the
molecular weights of rFcnB and rFcnBs2-1 were reduced
to 33kDa and 31–33kDa, respectively. Treatment of rFcnB
with endo-α-N-acetylgalactosaminidase resulted in a slight
reductioninthemolecularweightto36kDa,whiletreatment
of rFcnBs2-1 had no eﬀect. The N-terminal amino acid
sequence of rFcnB was T20CPELKV, indicating that the
preceding19aminoacidswereremovedasasignalpeptideby
the host CHO cells. The N-terminal sequences of the 35kDa
and 33kDa bands of rFcnBs2-1 were RSPWPGVFV15HAAG
and A18GTCPEL, respectively, indicating that the 35kDa
band corresponded to our designed rFcnBs2-1 product con-
taining the eight plasmid-derived amino acids (underlined)
at the N-terminal [18], and the 33kDa band was another
rFcnBs2-1 product with a diﬀerent N-terminal, which was
processed by Drosophila S2 cells.
Oligomeric rFcnB was subjected to gel chromatography
to determine its size distribution. It was found that, like
native FcnB, the main rFcnB species was eluted in theJournal of Biomedicine and Biotechnology 5
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Figure 4: Complement activation by rFcnB/rMASP-2/rsMAP com-
plexes. Upper panel: western blot of FcnB and MASP-2/sMAP. After
incubation of the recombinant proteins as shown in the table,
the generated complexes were pulled down by GlcNAc-agarose
and subjected to western blotting. Lower panel: C4-deposition
activity of the similar pull-down samples on GlcNAc-BSA-coated
microplates. The samples used for C4 deposition were prepared
the same as those for western blotting except for employment of
rMASP-2a instead of rMASP-2i. The activity was determined in
quadruplicate (mean ± SD).
range corresponding to 100 to >1000kDa with a peak
around 600kDa (Figure 3(b)). A minor band was observed
at 33kDa in the rFcnB preparation eluted between 100 and
200kDa. These results indicate that the rFcnB preparation
contains a major 12–18-mer made up of 37kDa monomers,
and a minor 3–6-mer made up of 33kDa monomers. Gel
chromatography of rFcnBs2-1 showed that this protein
ranged from 100 to 300kDa, suggesting that it is a 3–9-mer
composed of 33–35kDa monomers.
To conﬁrm the interaction between rFcnB and MASPs
and sMAP, rFcnB was incubated with rMASP-2i and rsMAP
and then subjected to FcnB pull down using GlcNAc-
agarose. As shown in Figure 4,r M A S P - 2 ia n dr s M A Pw e r e
coprecipitated only in the presence of rFcnB. Coincubation
of rMASP-2i and rsMAP resulted in reduced binding to
rFcnBcomparedwithincubationwitheachalone,suggesting
their competitive bindings to rFcnB. The rFcnB/rMASP-
2a complex activated C4 on GlcNAc-coated microplates.
This C4-deposition activity was inhibited in part by rsMAP.
In addition, rFcnB bound to rMASP-1i and rMASP-3,
and this binding was partially inhibited by coincubation
with rsMAP (Figures 5(a) and 5(b)), suggesting that FcnB
associates with all types of MASP and sMAP in a similar
manner.NoactivationofrMASP-3wasobservedunderthese
experimental conditions, even when it was complexed with
rFcnB on GlcNAc.
4. Discussion
The present study clearly indicates that, like rat recombinant
FcnB, both native and recombinant forms of mouse FcnB
associate with MASPs and sMAP. It also demonstrates that
FcnB/MASPs/sMAP complexes activate C4 on immobilized
GlcNAc. Taken together with the results of Girija et al. [19],
these results suggest that at least a part of murine FcnB
essentially executes its function through the lectin pathway.
In the present study, it was observed that the monomer
size of FcnBs2-1 was smaller than that of the native FcnB
andrFcnB proteins, largelyduetothe N-linked carbohydrate
content. It was also found that FcnBs2-1 formed smaller
oligomers (3–9-mers), in contrast to the highly oligomeric
forms of the native FcnB and rFcnB (12–18-mers). These
results simply suggest that the processing of proteins in
insect cells is diﬀerent from that in mammalian cells. To
conﬁrmthis in the presentstudy,weprepared a third formof
recombinant mouse FcnB, termed rFcnBs2-2, in Drosophila
S2 cells. The N-terminal residue of rFcnBs2-2 was adjusted
to Thr20 as same as that in rFcnB, which was performed by
ligation of a FcnB cDNA containing an extra six bases into a
pMT/Bip/V5-His A vector. The generated rFcnBs2-2 showed
a molecular weight of 31kDa under reducing conditions,
and treatment with endoglycosidase F reduced this to 30kDa
(data not shown). It was also found that rFcnBs2-2 was less
oligomeric, existing mainly as 3–6-mers, and that it failed to
associate with rMASP-2i or rsMAP (data not shown). These
results clearly indicate that the processing of recombinant
mouse FcnB in Drosophila S2 cells is diﬀerent from that in
mammalian cells.
Aninterestingresultwasobservedingelchromatography
of the rFcnB preparation, which contained a major and
highly oligomeric species comprising 37kDa monomers
and a minor and poorly oligomeric species comprising
33kDa monomers (Figure 3(b)). In a preliminary study,
we observed that culture of CHO cells in the presence
of tunicamycin, an inhibitor of N-linked glycosylation,
resulted in the preferential production of rFcnB comprising
33kDa-monomers, which was also less oligomeric (3–6-
mers) (data not shown). These results suggest that full N-
linked glycosylation of FcnB is essential for high level of
oligomerization.
We recently observed that Drosophila S2 cells produced
trimers of human H-FCN, while CHO cells produced highly
oligomeric H-FCN (∼18-mers), which were structurally
similar to native H-FCN in human serum (data not shown).
However, Drosophila S2 cells do not always produce less
oligomeric ﬁcolin. For example, this cell line successfully
produced highly oligomeric forms of mouse FcnA and
human M-FCN (∼600kDa) [17, 18]. At present, the reason
why ﬁcolin molecules are processed diﬀerently in Drosophila
S2 cells it is not known. One possibility might be a small
diﬀerence among these ﬁcolins in the amino acid sequence
that forms the N-linked glycosylation site, for example, the
surrounding sequence around Asn-X-Ser/Thr.
Our studies, including the present study, demonstrate
that, regardless of the type of host cell used, recombinant
ﬁcolins expressed as highly oligomeric forms associate with6 Journal of Biomedicine and Biotechnology
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Figure 5: Complex formation between rFcnB and rMASP-1i (a) and rMASP-3 (b). After incubation of the recombinant proteins as outlined
in the table, samples pulled down with GlcNAc agarose were subjected to western blotting. Western blotting for rMASP-1i, rMASP-3, and
rsMAP was performed using an anti-penta-His tag Ab.
MASPs/sMAP, while less oligomeric forms do not. Thus, it
is suggested that full processing including N-linked glyco-
sylation is essential for the formation of highly oligomeric
ﬁcolin and that high oligomerization is in turn essential
for association with MASPs and sMAP. At least, it can be
concluded from our studies that CHO cells are available
to produce highly oligomeric recombinant for all types of
ﬁcolin.
The molecular mechanism underlying the activation of
the lectin pathway by mouse FcnB appears to be similar
to that of other mammalian ﬁcolins, at least in terms of
complexformationwithMASPs,sMAP,andprobablyMap44
(MAP-1) [25] and in activating C4, possibly C3 and C2
on targets. However, it is unclear as to how strongly FcnB
exerts its activity through the lectin pathway in vivo and
as to how FcnB shares its activity with FcnA and MBLs.
It is noteworthy that, in the present study, rMASP-3 was
not activated when complexed with rFcnB on GlcNAc. The
rFcnB/rMASP-3complexmaybeusefulforidentifyingnative
target molecule(s) recognized by FcnB.
5. Conclusions
FcnB was identiﬁed in mouse bone marrow ﬂuid as a
highly oligomeric protein. GlcNAc-agarose chromatography
of bone marrow ﬂuid showed that FcnB was present in
a complex with MASP-2 and sMAP. This complex also
exhibited C4-deposition activity on immobilized GlcNAc.
These results were conﬁrmed using rFcnB produced in CHO
cells. Comparison of the biochemical features of the three
types of the recombinant ﬁcolin, rFcnB, rFcnBs2-1, and
rFcnBs2-2, suggests that full processing, including N-linked
glycosylation, is essential for oligomerization of FcnB and its
association with MASPs/sMAP. Taken together, we conclude
that mouse FcnB acts as a recognition molecule working
through the lectin pathway. To further understand the role of
murine FcnB, its location site and real target(s) and the pre-
cise stoichiometry of the FcnB complex need to be clariﬁed.
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